| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0449 | FIMM | pan-cancer | AAC | -0.1 | 0.6 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | sotrastaurin | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |